2026-03-30 - CoA - Sinocare et al. v. Abbott - UPC-COA-0000899/2025

Aktenzeichen:
UPC-COA-0000899/2025
Datum:
Spruchkörper:
Court of Appeal - Luxembourg (LU)
Art:
Final Order
Parteien:
Sinocare Inc., A. Menarini Diagnostics s.r.l. v. Abbott Diabetes Care Inc.

Kernaussage: ENGLISH:

2026-03-30 - CoA - Sinocare et al. v. Abbott - UPC-COA-0000899/2025
🏛️Court of Appeal - Luxembourg (LU)• Final Order
📅2026-03-30
🔢UPC-COA-0000899/2025
Parteien & Vertreter
Kläger / Berufungsführer
Sinocare Inc.
A.Menarini Diagnostics s.r.l.
Tjibbe DOUMA
Edoardo BARBERA
Beklagter / Berufungsbeklagter
Abbott Diabetes Care Inc.
Christian DEKONINCK
⚖️Appeal RoP220.1
🌐English

ENGLISH: 1. By not contesting the jurisdiction and competence of the Court in First Instance, the Appellant (Defendant in first instance) has in principle foregone this opportunity on appeal and cannot raise the alleged lack of jurisdiction and competence as a ground for overturning the impugned order (Art. 26(1) Brussels I Recast and R. 19.7 RoP). 2. By manufacturing, preparing and selling allegedly infringing products intended for the Contracting Member States of the UPC, there is a likelihood of damage occurring in the UPC territory arising from the possibility of third parties obtaining these products in the Contracting Member States, even if the acts causing the damage are performed by the Defendant outside the Contracting Member States. This provides basis for jurisdiction of the UPC pursuant to Art. 71b(2) in conjunction with Art. 7(2) Brussels I Recast. 3. Appellants must demonstrate that any alleged procedural or substantive errors by the Court of First Instance, such as those in relation to the procedural schedule applied in first instance, have resulted in an incorrect decision by the Court of First Instance. In the absence of such a showing, the alleged errors cannot result in setting aside the impugned order.

notable
CoA (five-judge Panel 3) rejects appeal against The Hague LD's preliminary injunction. Comprehensive decision covering jurisdiction over Chinese manufacturer (Sinocare) and Italian distributor (Menarini), claim construction of CGM sensor assembly features, full validity review (added matter, sufficiency, novelty, inventive step all rejected on balance of probabilities), and infringement confirmed. Urgency established despite pre-grant knowledge — the relevant trigger is patent grant, not knowledge of infringement. Generally worded injunction upheld. Interim cost award of EUR 200,000 (50% of EUR 400,000 ceiling). Important holdings on jurisdiction over non-EU manufacturers under Art. 71b(2)/7(2) Brussels Ia, failure to contest jurisdiction as estoppel on appeal, and standard for PI necessity in the CGM market.
Stichwörter
ENGLISH: Jurisdiction – Claim construction – Infringement – Validity (added matter, sufficiency, novelty and inventive step) – Urgency, necessity and balance of interests

Nichtigkeitsgründe

Art. 138 EPC
4 Gründe
Novelty
Art. 54 EPC · Art. 138(1)(a) EPC
Patent survived (this ground)
“Not more likely than not that patent is anticipated by US833 (Dexcom) or WO896. US833 discloses substantially different sensor system without pre-assembled sensor assembly. [136-185]”
Inventive Step
Art. 56 EPC · Art. 138(1)(a) EPC
Patent survived (this ground)
“No pointer from US833 or WO896 to modify sensor system to arrive at claimed invention. Motivation cited by appellants was already fulfilled by US833's own disclosure. Follows Amgen v Sanofi/Regeneron inventive step framework. [186-208]”
Added Matter
Art. 123(2) EPC · Art. 138(1)(c) EPC
Patent survived (this ground)
“New added matter arguments against claim 1 disregarded under R. 222.2 RoP — could have been raised in first instance. Claim 15 argument also excluded. On substance, no added matter found. [121-130]”
Insufficiency of Disclosure
Art. 83 EPC · Art. 138(1)(b) EPC
Patent survived (this ground)
“Patent discloses at least one way of performing the invention (Figures 34A-34D). Skilled person (interdisciplinary CGM engineering team) can carry out the invention. Follows Amgen v Sanofi/Regeneron sufficiency framework. [131-135]”
Feststellungen aus Sicht des Patentinhabers bezeichnet. Quelle: KI-Klassifikation (AI)

Entscheidung teilen

Weitere Navigation
Entscheidungen
Rechtstexte
Analysen

Zu Sammlung hinzufügen

0 Einträge hinzufügen zu:

Anmeldung

Registrieren